Drugs / VT-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06632964 | Sep 2024 → Sep 2025 overdue | urinary bladder carcinoma | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06632964 ↗ |
| Route | Other | “Method of administration: intravesical perfusion” NCT06632964 ↗ |